The KRT19 Knockout Ca Ski Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population derived from Ca Ski cervical carcinoma cells, with disruptive editing of the KRT19 gene. This heterogeneous pool enables loss-of-function analysis of keratin 19 without clonal selection, suited for studying its structural and signaling roles in epithelial cancer.
The Ca Ski host line, isolated from an epidermoid cervical carcinoma metastasis, exhibits adherent epithelial morphology and integrates human papillomavirus type 16 (HPV16) genomes. It endogenously expresses HPV16 E6 and E7 oncoproteins and displays metastatic potential, making it a classic model for HPV-driven cervical carcinogenesis.
Keratin 19 (KRT19) is a type I intermediate filament protein that forms obligate heteropolymers with type II keratin KRT8, creating the cytoskeletal scaffold essential for epithelial mechanical integrity, adhesion, and signaling. Its expression is regulated by p63, AP-1, retinoic acid, TGF-??, and EGF. KRT19 filaments interact with desmosomal plaque proteins (plakoglobin, desmoplakin) and hemidesmosome components, and bind directly to 14-3-3 zeta and Akt1, tethering the intermediate filament network to PI3K/Akt survival signaling. Focal adhesion kinase (FAK) further connects KRT19-based filaments to cell-matrix adhesion dynamics. KRT19 also participates in desmosome assembly and hemidesmosome stability, critical for tissue cohesion.
In the Ca Ski context, KRT19 knockout disrupts the keratin cytoskeleton, impairing cellular stiffness, adhesion, and migration. Combined with HPV oncoprotein activity, KRT19 loss may attenuate Akt-mediated survival and FAK-dependent adhesion signals, potentially suppressing metastatic traits. This model is thus valuable for probing how intermediate filament integrity influences viral transformation, epithelial-to-mesenchymal transition (EMT), and therapy resistance in cervical cancer.
Applications include immunofluorescence to visualize keratin network disruption, co-immunoprecipitation for assessing KRT8-14-3-3-Akt complex integrity, phospho-Akt ELISA, and functional assays such as wound healing and Transwell invasion. Additionally, flow cytometry and Annexin V staining measure apoptosis, while RT-qPCR and Western blotting confirm KRT19 ablation and downstream changes. For further information, please contact Ascent Research.
